Pan-cancer analysis identifies tRNA modification enzyme CTU2 as a novel tumor biomarker and its role in immune microenvironment
CTU2 may serve as a valuable prognostic and immunotherapeutic biomarker across multiple cancer types, providing new insights into tumor treatment strategies and immune evasion from the perspective of tRNA modifications.
Authors
- Jiaojiao Wang (ORCID: https://orcid.org/0000-0002-2265-7957)
- Huahong Luo
- Siqi Dai (ORCID: https://orcid.org/0000-0002-5729-6768)
- Junyi Zhang (ORCID: https://orcid.org/0000-0002-0001-2971)
- Jianwei Wang (ORCID: https://orcid.org/0000-0002-1116-4559)
- Chang Gao (ORCID: https://orcid.org/0000-0002-1207-7457)
Institutions
- Zhejiang International Studies University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.3389/fimmu.2025.1547794
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00